- Home
- TVTX vs TGS Comparison
TVTX vs TGS Comparison
Compare TVTX & TGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVTX | TGS |
|---|---|---|
| Founded | N/A | 1992 |
| Country | United States | Argentina |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Natural Gas Distribution |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.6B |
| IPO Year | 2013 | 2002 |
Fundamental Metrics
Financial Performance| Metric | TVTX | TGS |
|---|---|---|
| Price | $59.10 | $26.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 1 |
| Target Price | ★ $40.62 | $40.00 |
| AVG Volume (30 Days) | ★ 1.4M | 207.0K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 3.01% |
| EPS Growth | ★ 92.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $44.76 | $2.13 |
| Revenue Next Year | $35.51 | N/A |
| P/E Ratio | ★ N/A | $17.56 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.06 | $20.01 |
| 52 Week High | $68.73 | $36.35 |
Technical Indicators
Market Signals| Indicator | TVTX | TGS |
|---|---|---|
| Relative Strength Index (RSI) | 37.84 | 30.66 |
| Support Level | $53.76 | N/A |
| Resistance Level | $59.93 | $31.88 |
| Average True Range (ATR) | 2.57 | 0.82 |
| MACD | -0.91 | -0.29 |
| Stochastic Oscillator | 10.09 | 0.65 |
Price Performance
Historical ComparisonAbout TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
About TGS Transportadora de Gas del Sur SA TGS
Transportadora de Gas del Sur SA is a natural gas transporter in Latin America. The company's operating segments include Natural Gas Transportation, Midstream, Telecommunications, and Liquids Production and Commercialization. It generates maximum revenue from the Natural Gas Transportation segment. Geographically, it derives the majority of its revenue from Argentina.